The IPO Playbook: Evidence, Agility, and Investor Trust | David Iannetta

Not seeing investor-grade pipeline from your science? Bill is the Fractional CMO for complex medtech & life-sci GTM. Book a 20-min diagnostic.  https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/ 

• Connect with Dave Iannetta on LinkedIn: https://www.linkedin.com/in/dave-iannetta/
• Subscribe to Bill Schick’s Newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7154518390324281344

00:00 The IPO Playbook
02:30 Being Unprepared for IPO
04:30 Data & Market Validation
06:05 FDA Changes in 2025
09:27 Tips for Creating an IPO Deck
13:23 Messaging for IPO

About this episode: Early funding rounds reward vision, but the IPO process rewards verification. David joins me again to walk through the journey from institutional capital to public offering and shows how every assumption that once lived in a slide note must now survive legal discovery. He recalls deals that stalled because total-addressable-market figures lacked primary sources and others that crumbled when an FDA setback forced a last-minute pivot the team could not explain. His core message: a marketer’s real job at this level is to translate complex clinical value into a dollar-based opportunity that bankers can model and retail investors can grasp in two sentences.

Three IPO Musts: 
1. Treat market sizing the way a biostatistician treats a primary endpoint. Start with bottom-up data such as procedure volumes from CMS, epidemiology registries, or detailed purchase-order pulls from group-purchasing organizations. Build the model cell by cell so any analyst can trace volume, price, and adoption-rate assumptions back to a public document or a signed customer quote. Keep totals in three buckets—total addressable market, serviceable market, and realistically obtainable share—so you are never accused of using a single inflated figure. A grounded model not only survives diligence but also shapes banker sentiment; if you claim a four-billion-dollar market and the underwriters later pin it at one, you can lose half your valuation before the first road-show slide appears.

2. Create a living archive for every assumption that feeds your financials. Store PDFs of journal articles, invoices that justify cost inputs, raw spreadsheets, and even audio transcripts of expert interviews in a well-indexed data room. Each time a figure changes—perhaps because new coding data arrive or the FDA requests a larger trial—update the archive and note the version in your working deck. Bankers, lawyers, and syndicate analysts will audit each cell in your spreadsheet against its original source; if you have to scramble for proof after the S-1 is filed you will burn weeks, pay extra legal fees, and lose the momentum that makes an IPO window attractive in the first place.

3. Build your narrative as a living document that flexes with every regulatory update or clinical read-out. Investors do not punish a company for hitting a speed bump; they punish it for ignoring the bump or pretending it did not happen. Hold regular “story scrubs” where marketing, clinical, and finance teams rewrite the pitch deck in light of the latest data, resize the market if endpoints shift, and script a clear path forward. Practising this iterative storytelling prevents the deer-in-the-headlights moment when a diligence call surfaces new questions and shows investors that the team can navigate uncertainty as confidently as it develops science.

For more specialized help with growth, check out my firm, Mesh.
https://meshagency.com/ 

#IPOReady #LifeScienceMarketing #MarketSizing

Transcript

0:00

As a marketer, you still have your day job, which is figuring out how to commercialize whatever the product is. And then, oh, by the way, you have to sort of build out the IPO day. That's easier said than done. So today I speak again with Dave. I neta he is a seasoned marketing exact with a lot of experience working with companies at different stages of funding. You are trying to explain a perhaps very complex, clinically challenging process and pathway to an audience that may be less familiar. This is our third segment on how to market a little bit differently, depending on the stage of funding you're at. Our conversation today is really focused on what you should be doing when you're looking at IPO at an IPO level now, you really are talking commercialization and how does it fit in the market? What is that market opportunity truly looks like, and how do we actually take this product and start to capture it? Welcome to life's AI continuum. Let's go. So thinking about our sort of our next level if you will IPO quickly maybe bridge the distance between okay I've got some sort of institutional investment. Summarize that journey to IPO and in a minute or two. So we can we can talk about that a little bit. Yeah. You know you kind of think about the evolution of the story that we've talked about sort of in the early days. It's understanding what is the process to get you sort of more validation and to get you perhaps into human testing. Then the next phase is how do you take that and sort of turn it into a product and understanding the clinical application and the the fit for patients and the need that patients have for it at an IPO level. Now you're you really are talking commercialization. And how does it fit in the market. What does that market opportunity truly look like. And how do we actually take this product and start to capture it? It's very much a commercially driven. This is where we're going. This is what the opportunity looks like. And I think probably to me, the the biggest evolution in the story is you need to be absolutely crisp with the size of the market, how you define all those things, where is it going and what you know? What truly does the market potential look like? And that's probably the biggest shift at that stage, is really having a good, crisp story. Not that you don't need those earlier, but it just gets more and more. You know, very tightly defined. And I think that's an important evolution. Have you ever seen or heard of a situation where maybe a company got to this stage and then didn't have the pieces in place? That's a good question. You're probably not going to get very far past the stage if you don't have some of those. If you don't have those things in place or at the least, you know, valuations suffer as a result. So I mean I think you're certainly well served to have that story in place. And that's where at that at that point you know a lot of your partners, whether it's lawyers or IPO bankers, I mean they'll be they'll be helping you kind of tell that part of the story. So yeah it's it's certainly important. I mean have you have you seen examples where the kind of falls apart at this stage. I don't know if it, it falls apart. It might it might get a bit rocky. And of course people come together to save the day. My experience is especially with maybe smaller companies, sometimes there's an attitude of, well, we don't we don't really need that. I understand that a lot of companies and you can fill in that, whatever that is with a lot of different things. But some of the mentality is, well, we're addressing such a huge opportunity, are such a huge need. Well, all we have to do is tell people about it and it will everything will fall into place. And so they don't have they don't really look at what the market is for it. For example, a company that goes that has an initial, investment of 1.5 million and they get to a stage, they, bring in a firm, a firm looks at it and I think they may have had a junior analyst on, and they did some quick numbers and they thought it was fine. And then they, they went further along and they were really struggling. And what it, what it turned out is it just wasn't a big enough need or opportunity. And the money wasn't working. So they had to pivot a little bit. I'm trying to be yeah, I'm big, but I think some of the the data and the market validation that you can get early on is important. And I don't think it always gets done. And you would hope that if you go through the gate of having an institution behind you, so some sort of investment group, they would be present and be driving you to even through the process of bringing them in, have all that in place. Yeah. I mean, certainly I think I've seen where expectations or assumptions change along the way. And you have to do sort of a, forced pivot. I mean, that certainly that happens based on what you learn in the process, you know, that can be disruptive and in a lumpy process. But, you know, sometimes that's that's the way it goes. And you might, you know, perhaps you get towards the IPO process and then you have to reset and go back and figure out something else along the way, because, you know, you have a setback with the FDA or something else, comes up. I mean, those those are certainly real situations. And, you know, I think along the way it's just being able to explain that story, of what we learned and what what happened along the way that that's what I've seen. If it doesn't go forward, it tends to be more of a setback driven FDA or some type of, clinical study failure. You know, you didn't meet your end point, something like that, that you had to go back and retool and that, you know, that's a that's a fact of life for sure. And that made me take, the whole new story. Right? I mean, maybe you have to go back and start start from scratch, or at least kind of a new whiteboard approach of how are we going to explain this, given this, you know, particular product failure? And that's certainly that's a fact of life for sure. So I'm going to throw you a curveball because I think there's a there's a lot of discussion right now about what may or may not happen in the coming year or two with the FDA. And how that may impact everything in what we do. Any thoughts or opinions or. Yeah, it's a good question. I mean, it's certainly one that's been on my mind the last couple days in particular. I think on on one hand, the regulations and everything are it's a blessing and a curse, but sometimes they're slow to move. Now, I suppose what you know, some of the discussions is, is speeding up some of those changes so that that's certainly a question. I mean, I think at some level, the clinical data that companies have gotten into the habit of producing, I think that will still speak for itself. I think when you look at the evidence that you have to put together, I don't see that changing necessarily. I mean, you know, proper clinical study with real endpoints, is going to drive a lot of the discussion. I think, you know, areas that might get more challenging or, you know, if there are certain sort of process steps around pre-clinical or the kind of phased development process, if that changes, you know, we'll just have to roll with it. I think companies are good at it rolling with it, but it'll certainly take some of your, investor decks and throw those for a loop if you have to. Do you know, another set of studies or something like that? I mean, those are certainly questions for sure. I don't know, I mean, what what have you seen, what have you seen people talking about relative to I, I've heard all manner of perspectives on, what may or may not happen. Fewer certainly, that have a more sort of clinical view than you. I am wondering about something you just said, which is around the clinical steps. Can you look back in either memory or in in something that you've seen where there was a big enough? I don't want to say seismic, but a big enough change and shift where companies had to make a change. I think I think there are always ongoing shifts in how things work. I think the concern is that this time things might be a little bit bigger. Yeah. I'll give you one example that that certainly on, on my mind of, of the types of things to, to watch for the orphan drug statutes have been around for, for quite a while at this point, and they've been used to drive a tremendous amount of development and clinical benefits for, for patients. Right. But with that comes product exclusivity. And, you know, you get seven years of, of exclusivity on a, on an indication if something like that were to change. I mean, it certainly makes it, you know, a more difficult process, to think through commercialization. And how does that work and how much investment does it need? And that changes the calculus a little bit on, on some of those products. So that's, that's not an easy one, but that's one that occasionally gets flagged for, discussion. So, you know, if you change some of the fundamentals, I mean, that would take something to get looked at. You know, I don't have a crystal ball as to how that would go, but it would certainly impact a lot of, investment decisions for sure. Yeah. There are a lot of questions right now. I'm wondering, is there anything else that somebody is is preparing to. They're really looking at drafting a narrative that resonates with their investors. We've we've sort of touched on the three types of, investment that you might be seeking. And how you might approach that. Is there anything else that any other tips or recommendations you might have for people as they're starting to play in this process? Because really, you want to be having a, a bit more of a holistic view upfront of what this journey looks like. Any quick recommendations for getting going on the right foot? Two ideas. One is kind of building on what we talked about. I think there's a fundamental question of storytelling. You you are trying to as a marketer, you are trying to explain a perhaps very complex, clinically challenging process and pathway to an audience that may be less familiar. So that is both a challenge and also an opportunity. I think that's where as a marketer, you can really shine at being a storyteller. And being able to explain how something very complex and be able to distill it down very simply, that is not an easy task. But I think, you know, for for all of us, I think that's that's part of the opportunity that we do in marketing is how do we tell those stories. So and that sort of builds along the way. The story may change over time as we talked about, but fundamentally, you're trying to tell the story of, of not just the product but the company. So that's sort of high level how I think about the opportunity. But the second one is a little bit of a more practical, advice, which is, and I would say sort of hard one lessons around this is document all of your assumptions, particularly in as you build out your market assessment and you sort of build the market opportunity story. Boy, oh boy, just document all that stuff because it will come back to bite you. When you're going through eventually when you get especially with the IPO process. I mean, you have to document every single number, every number that's in the prospectus needs a back up. And, you know, I'll give you an example, like, you know, you look at things, lately I'm working on a product in the coronary PCI, space. So percutaneous coronary interventions, it's basically for, you know, stents and things like that. And it's a pretty common assumption that in the US there's roughly a million PCI procedures. And you can find that number in a million different places. But they're all like other pitch decks like yours. And what I found is that you can't reference someone else's reference. You need to actually go to sort of ground truth and find that find that actual data point for your IPO. Lawyers will shoot it down. And when they shoot down a number like how many patients there are, man, that really messes up a lot of your assumptions. So having all of that along the way, you will save yourself a lot of time and headache to keep all that information in one place that's easily accessible, so that when the time comes that you need all those, data points, you have it. And that's something I would say the first time I went through the process. Less good, the second time much better. And being able to to just quickly. Because what happens is I think with the, with the process, you know, you sort of get into these, fundraising efforts and it tends to be as a marketer, you know, you still have your day job, which is figuring out how to commercialize whatever the product is that you're working on. And then, oh, by the way, you have to sort of build out the IPO deck. That's easier said than done. And to save yourself the time and effort by having a lot of that material already gathered, I think is a is a big one. Yeah, I think so. And looking at this through the lens of messaging to reference and put your hands on, any of your data on your source, at any point that got you to the point. So if, if you go along the journey and there these twists and turns and then you have to go back and this is, this is a bit more protective than, than forward looking strategy, but they kind of blend. If you, if you go kind of along those twists and turns, making it kind of making shifts in messaging, maybe, somebody may, you know, pop their head up further down the road and say, well, I saw you referencing this in an ad over here. You know, it was it was a really cool campaign, except you have this data point that's going to get us in a lot of trouble being able to get your hands on that, beyond just kind of, you know, messaging to investors, I think is is key. And I think sometimes as, as maybe more creative thinkers, some marketers in the space may not be as organized for some of that, but I would hope that most of the people that we've worked with, we've seen, are much more organized and can put their hands on their data very quickly where the challenges happen or, you know, inevitably, as a as a head of marketing at a small company, you know, you're probably not the first hire, right? So the company has existed before you got there. Maybe they've already raised money before you got there. They probably have. So the bigger challenge is, is, you know, you walk into some existing materials and then it's like, oh, I need the reference for that. Well, I don't know where that came from to begin with and to have been through that exercise, which is fun. But that's that's part of the process. Right. So you have to go back and figure out how are we going to back that up, how are we going to document those things. And you know, more often than not you can do it. But sometimes you have to kind of tweak your messaging a little bit to make sure that you, you actually have stuff that you can, document and stand behind. But I've seen that, you know, many times over the years where, you know, there's a slide that the CEO loves that he put together eight years ago. And, you know, you keep using it. But then when you get there, you're like, well, I don't know where these numbers came from. Right. And but that's part of the story is figuring out, okay, how are we going to do this? And if we need to change it like we can. But, you know, working through that process is certainly it's an adventure. Dave, thank you so much. It's good talking to you again. Sounds good. All right Bill, thanks. So if you're a life science leader or product manager and you have an interesting story you'd like to share, reach out to me on LinkedIn and we'll connect you. If you're interested in learning some other lessons in marketing for life sciences, or in avoiding some of the big mistakes, I cover a lot of that in my LinkedIn newsletter, so I'll drop the links to those in the description below. That's it. That's the end.